Hanlon et al. study the prevalence of frailty and multimorbidity in a cohort of 20,566 UK Biobank participants with type 2 diabetes aged between 40 and 72 years. They observe that, even in this relatively young population, people living with frailty and/or multimorbidity are at increased risk of adverse outcomes including mortality, major adverse cardiovascular events, and hypoglycaemia.
- Peter Hanlon
- Bhautesh D. Jani
- Frances S. Mair
